FAM方案经动脉灌注治疗晚期胃癌的疗效分析  

An Analysis of the Effects in the Treatment of Advanced Stage Gastric Carcinoma through Arterial Perfusion by means of FAM Program

作　　者：郑登云[1] 麦大海[1] 何志江[1] 

机构地区：[1]广东省茂名市人民医院肿瘤科,525000

出　　处：《肿瘤防治研究》2000年第5期406-407,共2页Cancer Research on Prevention and Treatment

摘　　要：目的　比较FAM方案动脉灌注与静脉给药对晚期胃癌的治疗效果。方法　 4 3例晚期胃癌患者随机分为两组 ,均用FAM方案 ,剂量基本一致 ,其中动脉灌注组 2 2例 ,静脉化疗组 2 1例。结果　动灌组完全缓解率 18 2 % ( 4 2 2 )总有效率 68 2 % ( 15 2 2 ) ;静化组完全缓解率 9 5% ( 2 2 1) ,总有效率 38 1% ( 8 2 1)。两组间总有效率有显著性差异 ( χ2 =3 90 31,P <0 0 5)。中位生存期为 8个月和 6 5个月 ,差异无统计学意义。骨髓抑制率两组无显著性差异。胃肠道反应均较轻。结论动脉灌注FAM方案治疗晚期胃癌局控率优于静化组 ,但中位生存期两组无显著性差异。The purpose of the research is to compare the effects in the treatment of advanced stage gastric carcinoma respectively by arterial perfusion and by intravenous injection with FAM program.Methods Forty three patients with advanced stage gastric carcinoma were randomly divided into two groups.Both groups,given approximately the same dosages,were treated with FAM program.Twenty two patients were in the arterial perfusion group and twenty one were in the intravenous injection group.Results The general alleviation rate for the arterial perfusion group was 18 2%(4/22) and the overall effective rate was 68 2%(15/22),while the general alleviation rate for the intravenous injection group was 9 5%(2/21) and the overall effective rate was 38 1%(8/21).The difference between the overall effective rates of the two groups was significant ( χ 2=3 9031; P <0 05).The subsistence periods of two groups were respectively 8 months and 6 5months without any statistic significance.In terms of the inhibition rate on bone marrow,the two groups had no difference.Besides,the patients just had very slight gastric and intestinal reactions.Conclusion The arterial perfusion group treated with FAM program for advanced staged gastric carcinoma had higher local control rate than the intravenous injection group,but the two groups had no significant difference in subsistence period

关 键 词：晚期胃癌 药物疗法 FAM方案 动脉灌注疗法 疗效 

分 类 号：R735.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]